Your shopping cart is currently empty

ZLWT-37 is a potent, orally active inhibitor of CDKs, specifically targeting CDK9 (IC50: 0.002 μM) and CDK2 (IC50: 0.054 μM), and is capable of blocking the cell cycle of HCT116 cells in G2/M phase and inducing apoptosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $1,980 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $2,500 | 10-14 weeks | 10-14 weeks |
| Description | ZLWT-37 is a potent, orally active inhibitor of CDKs, specifically targeting CDK9 (IC50: 0.002 μM) and CDK2 (IC50: 0.054 μM), and is capable of blocking the cell cycle of HCT116 cells in G2/M phase and inducing apoptosis. |
| Targets&IC50 | CDK2:0.054 μM, CDK9:0.002 μM |
| Molecular Weight | 464 |
| Formula | C26H30ClN5O |
| Smiles | #N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.